Date | Title | Description | |
---|---|---|---|
27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
08 Nov 2023 | On P&L | The Company releases the press release related to the first nine months of 2023 financial results | Download |
08 Nov 2023 | On P&L | The Company releases the first nine months 2023 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
07 Nov 2024 | On P&L | A correction to the English version of a document is reported. | Download |
03 Oct 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2024 | Download |
12 Sep 2024 | Other relevant information | The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. | Download |
01 Aug 2024 | Other relevant information | The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. | Download |
31 Jul 2024 | Liquidity and counterparty agreements | Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |